RA
CYTK icon

Rise Advisors’s Cytokinetics CYTK Stock Holding History

Rise Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-476
Closed -$26.2K – 437
2025
Q3 		$26.2K Hold
476
– – 0.01% 436
2025
Q2 		$15.7K Hold
476
– – 0.01% 684
2025
Q1 		$19.1K Buy
476
+272
+133% +$12.5K 0.01% 520
2024
Q4 		$9.6K Hold
204
– – ﹤0.01% 989
2024
Q3 		$10.8K Hold
204
– – 0.01% 992
2024
Q2 		$11.1K Hold
204
– – 0.01% 977
2024
Q1 		$14.3K Buy
+204
New +$15.8K 0.01% 879

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Rise Advisors's CYTK Position: Q4 2025 in Review

Rise Advisors sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 476 shares — an estimated $26.2K sold.

Rise Advisors first reported a position in CYTK in Q1 2024 and held it in 7 quarters. The position peaked at $26.2K in Q3 2025. 431 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • Rise Advisors reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 476 Cytokinetics shares in Q4 2025, an estimated $26.2K.
  • Rise Advisors first reported a position in Cytokinetics in Q1 2024 and held it in 7 quarters.
  • Rise Advisors's Cytokinetics position peaked at $26.2K in Q3 2025.
  • 431 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.